Connecticut Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Connecticut Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,013	Closed	-$261K	–	339
2024 Q1	$261K	Buy	+2,013	New	+$247K	0.01%	279
2023 Q4	–	Sell	-3,567	Closed	-$432K	–	328
2023 Q3	$432K	Hold	3,567	–	–	0.03%	187
2023 Q2	$408K	Hold	3,567	–	–	0.03%	167
2023 Q1	$492K	Sell	3,567 -5	-0.1%	-$649	0.04%	139
2022 Q4	$463K	Buy	3,572 +1,559	+77%	+$181K	0.04%	119
2022 Q3	$223K	Buy	+2,013	New	+$203K	0.02%	179
2021 Q1	–	Sell	-2,000	Closed	-$341K	–	207
2020 Q4	$341K	Hold	2,000	–	–	0.04%	141
2020 Q3	$281K	Hold	2,000	–	–	0.03%	164
2020 Q2	$321K	Buy	+2,000	New	+$272K	0.04%	110
2020 Q1	–	Sell	-2,000	Closed	-$258K	–	156
2019 Q4	$258K	Buy	+2,000	New	+$202K	0.03%	143

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Connecticut Wealth Management's SRPT Position: Q2 2024 in Review

Connecticut Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 2,013 shares — an estimated $261K sold.

Connecticut Wealth Management first reported a position in SRPT in Q4 2019 and held it in 10 quarters. The position peaked at $492K in Q1 2023. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

Connecticut Wealth Management reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
Connecticut Wealth Management sold 2,013 Sarepta Therapeutics shares in Q2 2024, an estimated $261K.
Connecticut Wealth Management first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 10 quarters.
Connecticut Wealth Management's Sarepta Therapeutics position peaked at $492K in Q1 2023.
483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Connecticut Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.